 To determinate and to describe the clonal evolution, 30 DLBCL cases with available matched tumor DNA and plasma will be collected and analyzed by routinely applicable next generation sequencing NGS at the time of diagnosis, at mid treatment, at the end of treatment and at 12 months after diagnosis. 